After the Federal Trade Commission filed a lawsuit against the company, alleging anti-competitive practices, Bernstein analyst Stacy Rasgon says the lawsuit's contention that Qualcomm refuses to license its standards-essential IP to chipset competitors could ultimately be a "killer" of the company's QTL business. However, the analyst adds that turnover on the commission could end up killing the lawsuit. Rasgon does not expect the lawsuit to impact the NXP Semiconductors (NXPI) deal, but recommends playing the deal through NXP rather than Qualcomm. Rasgon keeps a Market Perform rating on Qualcomm.

What has Wall Street been buzzing about this week? Here are the top 5 Bu-y calls and the top 5 Sell calls made by Wall Street’s best analysts during the week of April 22-26. Find all top-rated... To see the rest of the story go to thefly.com. See Story Here

Susquehanna analyst Christopher Rolland raised the firm's price target on Impinj (PI) to $150 from $140 and keeps a Positive rating on the shares. The firm said they posted a solid print with additional upside driven by the licensing win from NXP Semiconductors (NXPI). Customer engagements and new RFID markets continue to broaden the opportunity.

BofA raised the firm's price target on Texas Instruments (TXN) to $190 from $175 and keeps a Neutral rating on the shares. TI's small Q1 beat and inline but sequentially rising Q2 sales guidance, "while modest, potentially marks a recovery inflection in industrial chip demand," with positive read-across for U.S. peers such as Analog Devices (ADI), Microchip (MCHP), NXP Semiconductors (NXPI) and On Semiconductor (ON), the analyst tells investors. However, despite an expected recovery, TI's sustained high capex intensity could keep reported calendar year 2024-26 pro-forma EPS below $6 per share, the analyst added.